Brain Cancer

Temporal Lobe Glioblastoma

Female, 36 years

Patient Internal 103600474

ICD-10 code

C71.2 Malignant Neoplasm of Temporal Lobe

Diagnosis (Incl. Metastases/Stage) and Year

May 2020
Oligodendroglioma of the Temporal Lobe G3, 1p19q Coreletion (+), MGMT (+).

Previous Treatment

Surgery (Craniotomy), Radiation Therapy, Chemotherapy (Procarbazine, Lomustine, Vincristine).

Prognosis and Survival Expectation

The prognosis remains good, the median overall survival is 14.1 years for WHO Grade 3, 1p/19q Co-deleted Oligodendroglioma. The relative 5-year survival rate for Oligodendroglioma is 74.1%, but many factors can
affect prognosis.

Treatment Provided

Autologous DCV (6 doses) and CIK (4 doses) over a period of 6 months. Additionally, the patient received Umbilical Cord Blood Derived NK Cells (3 doses) with Interleukin-2.

Patient Survival/Condition and Year
Date of Review: 01/01/2024

The patient has survived for 44 months since the diagnosis. No signs of disease recurrence in radiological images have been noticed. It can be concluded that the addition of Immunotherapy, alongside Chemotherapy and Radiation Therapy, has benefited patient in disease stabilisation. There are no signs of disease recurrence so far.